Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 9/20 | 0.39 |
| ▸ | CCKBR | P32239 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.35 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.35 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.35 |
| ▸ | ITGAV | P06756 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5118137 | 1.00 | AGTR1 (0.39) | AGTR1CCKBRALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL5124424 | 0.97 | AGTR1 (0.37) | AGTR1ALDH1A1SMN1; SMN2RAB9AITGB3 | |
| SCHEMBL5114533 | 0.97 | AGTR1 (0.37) | AGTR1ALDH1A1SMN1; SMN2RAB9AITGB3 | |
| SCHEMBL14287334 | 0.93 | PARK7 (0.40) | CCKBRTRPV1PARK7ITGB3ITGAV | |
| SCHEMBL5111370 | 0.93 | PARK7 (0.40) | CCKBRTRPV1PARK7ITGB3ITGAV | |
| SCHEMBL5111360 | 0.93 | PARK7 (0.40) | CCKBRTRPV1PARK7ITGB3ITGAV | |
| SCHEMBL5145533 | 0.92 | MAPT (0.39) | ALDH1A1SMN1; SMN2TRPV1ITGB3ITGAV | |
| SCHEMBL5145524 | 0.92 | MAPT (0.39) | ALDH1A1SMN1; SMN2TRPV1ITGB3ITGAV | |
| SCHEMBL5110558 | 0.91 | PARK7 (0.40) | CCKBRTRPV1PARK7ITGB3ITGAV | |
| SCHEMBL5110405 | 0.91 | PARK7 (0.40) | CCKBRTRPV1PARK7ITGB3ITGAV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080004274-A1 | Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-01-03 | — | — | US | claimed |
| US-20080004274-A1 | Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-01-03 | — | — | US | disclosed |
| US-20080004274-A1 | Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-01-03 | — | — | US | disclosed |
| US-20080004274-A1 | Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004274-A1 | Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARD, PPARA | AGTR1 638/4885CCKBR 2480/4885ALDH1A1 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.